BioVision Lilly Award names winners
Four young scientists living and working in a developing country take the accolades
The winners were selected from among 40 entries by an international jury, chaired by Jacob Palis, president of TWAS, and professor at the Instituto Nacional de Matemática Pura e Aplicada in Rio de Janeiro, Brazil.
Digby Warner, senior research officer, MRC/NHLS/UCT Molecular Mycobacteriology Research Unit, University of Cape Town, South Africa won the 2011 BioVision Lilly Award for his work on mycobacterial metabolism, which promises to have a major impact on understanding the development of drug-resistance in Mycobacterium tuberculosis.
The runner-up was Thomas Scriba, senior researcher, South African TB Vaccine Initiative, University of Cape Town, who was honoured for his work on TB vaccines.
The first- and second-place winners received US$5,000 and US$2,000, respectively, to continue their research.
Dihandenys Lemus, Tuberculosis National Reference Laboratory in Havana, Cuba and Joy Sarojini Michael, Christian Medical College of Vellore, India were joint third. Lemus was honoured for her work in drug-resistant tuberculosis and Michael for her research in new TB diagnostics.
‘We have been impressed with the quality of the competition and especially the winners,’ said Bart Peterson, senior vice-president, corporate affairs and communication, Eli Lilly and Company.
‘TB largely afflicts the developing world and I’m heartened to see that young developing world scientists are taking their position at the forefront of global research being carried out into this debilitating disease.’
In 2009 more than nine million people became ill with TB and some 1.7 million died of the disease. The number of new cases arising each year is still increasing in Africa, Eastern Mediterranean and South-East Asia.
You may also like
Research & Development
Scientists develop new technique to fight antimicrobial resistance
The team of researchers from the University of Leicester have developed a new technique to sequence phage genomes from individual plaques and hopes to use it to build fully characterised libraries of bacteriophages, expanding the number of candidates available to tackle drug-resistant infections
Research & Development
Lancet Oncology Commission launches to examine future of academic cancer clinical trials amid funding and regulatory pressures
A global coalition of clinical investigators and patient representatives has launched the Lancet Oncology Commission to address the value and challenges of independent academic cancer clinical trials, amid growing concerns over regulatory complexity, limited public funding and the need for new international collaboration models
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
UK clinical trial reforms come into force in largest regulatory overhaul in 20 years
The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results
Research & Development
Epitopea receives MHRA approval for first-in-human trial of RNA vaccine for ovarian cancer
The company has received regulatory approval from the MHRA and Regional Ethics Committee to initiate its OVACT Phase I/Ib clinical trial of CryptiVax-1001, an off-the-shelf mRNA immunotherapy targeting high-grade serous ovarian cancer
Research & Development
NEUVIOR Pharmaceuticals receives Innovate UK grant to explore bio-based materials for circular pharmaceutical manufacturing
The Innovate UK feasibility grant will advance its ZYLON programme, which involves clean-chemistry lab trials exploring how bio-derived materials could replace harder-to-recycle packaging formats and reduce waste in pharmaceutical manufacturing
Research & Development
Awen Oncology secures seven-figure funding to advance rare bone cancer therapeutic programme
The cancer therapeutics company has secured seven-figure funding led by biotech investor Dr Urs Spitz to progress its lead programme targeting a rare form of bone cancer with potential broader oncology applications towards clinical development